Disease Modifying Antirheumatic Drug Market Report Size, Worldwide Industry Growth Analysis, Business Share and Revenue Forecast to 2023-2030 | AbbVie Inc., Eli Lilly & Company, Amgen Inc., Swedish Orphan Biovitrum AB

The Disease Modifying Antirheumatic Drugs Market is estimated to be valued at US$ 20,671.1 million in 2022 and is expected to exhibit a CAGR of 3.5% during the forecast period (2022-2030).

Market Overview:

Disease modifying antirheumatic drugs (DMARDs) are a class of drugs that help slow down the disease process and the progression of joint damage of rheumatoid arthritis. They work by targeting parts of the immune system that causes joint inflammation and swelling.

Market Dynamics:

Rising geriatric population vulnerable to rheumatoid arthritis and favorable reimbursement policies for DMARDs drive the market growth. According to the United Nations, the number of people aged 60 years and older is expected to double from 12% to 22% between 2015 and 2050 globally. Aged people are more prone to chronic diseases like rheumatoid arthritis which require lifelong DMARD treatment. Additionally, public and private health insurance plans provide coverage and reimbursement for the cost of DMARD therapy pushing the market. Moreover, various initiatives by governments and NGOs to raise awareness about rheumatoid arthritis treatment further propels the disease modifying antirheumatic drugs market growth.

Get an Exclusive Sample Copy of the Report at: - https://www.coherentmarketinsights.com/insight/request-sample/5185

Rising Prevalence of Rheumatoid Arthritis is Driving the DMARD Market

Rheumatoid arthritis is one of the most common autoimmune diseases where the body's immune system mistakenly attacks its own tissues. According to estimates, around 1.3 million Americans are affected by rheumatoid arthritis. With growing elderly population worldwide, the prevalence of rheumatoid arthritis is also expected to rise substantially in the coming years. As RA has no permanent cure, lifelong treatment is required to control the symptoms and slow down the disease progression. Disease modifying antirheumatic drugs or DMARDs are the standard treatment approach for rheumatoid arthritis patients. The rising prevalence of this immunological disease directly translates to increased demand for effective long-term DMARD therapies. Pharmaceutical companies are expanding their existing DMARD drug portfolios as well as progressing new drug candidates to tap into the high-growth market potential.

Increasing Research into Biosimilars and Novel Mechanisms of Action is Another Market Driver

The disease modifying antirheumatic drug market landscape is also evolving with continued research into biosimilars and novel mechanisms of action. A few blockbuster biologic drugs facing patent expiry are facing increasing competition from cheaper biosimilar alternatives. At the same time, companies are investing in research to develop next-gen DMARDs with improved efficacy, safety profile and convenient administration methods. Some of the new therapeutic targets being explored include JAK inhibitors, B-cell depletion therapies, anti-IL-6 therapies etc. This pipeline of novel therapies promises to significantly enhance treatment outcomes for rheumatoid arthritis patients. Their eventual approvals and commercial launches will likely drive the overall DMARD market growth due to substitution of older products as well as acquisition of new patient segments.

Patent Expiries of Major Drugs Pose a Key Market Restraint

A looming challenge that could impede the revenue growth of DMARD market is the patent cliff faced by some blockbuster drugs. Best-selling biologics Humira, Enbrel and Remicade have faced increasing biosimilar competition after their long-standing patents expired in recent years. These drugs previously accounted for a substantial market share. Their biosimilar entrants have substantially captured new patient volumes, resulting in erosion of innovator sales. Patent expiries of several other major DMARDs are also anticipated in the next few years that will enhance pricing pressure. While the potential of newer mechanisms and pipeline candidates exists, their revenues may not entirely offset the losses from off-patent products in the short-run. This threat of patent cliff remains a major restraint for pharmaceutical companies in this market space.

Biosimilars Present a Significant Commercial Opportunity

The emergence of biosimilar drugs provides a substantial commercial opportunity to expand the patient reach and drive higher sales volumes in the DMARD market. Besides offering more affordable options, biosimilars have the potential to treat greater number of underserved patients in different regions worldwide. With increasing biosimilar approvals and launches challenging blockbuster biologics, their market access strategies and pricing structures will likely shape the future competitive landscape. Major markets like the US and Europe have seen notable biosimilar uptake in recent years. Further market penetration of these cost-competitive biosimilars in developed and emerging countries can contribute significantly to the overall DMARD market growth. Companies optimally positioning their biosimilar portfolios stand to gain considerably.

Growing Adoption of Personalized Medicine Approaches is a Key Trend

An evolving trend in the DMARD market involves the growing adoption of tailored and personalized medicine approaches. With a deeper understanding of disease pathogenesis, research focus has expanded towards developing targeted therapies customized to patient subgroups based on specific molecular biomarkers. This includes therapies tailored for patients with different serotypes, stages of disease severity, concurrent conditions etc. Accompanying this is the wider adoption of companion diagnostics for genetically profiling patients and selecting the most appropriate treatment regimen. Improved patient stratification allows for more effective DMARD therapies with maximum efficacy and tolerability. The future of DMARD treatment lies in incorporating pharmacogenomics and realizing the full potential of precision medicine to transform patient outcomes.

List of TOP Players in Market Report are: -

◘ Sanofi.
◘ Pfizer
◘ F. Hoffman-La Roche AG
◘ Johnson & Johnson
◘ AbbVie Inc.
◘ Eli Lilly & Company
◘ Amgen Inc.
◘ Swedish Orphan Biovitrum AB
◘ Bristol-Myers Squibb Company
◘ UCB S.A.
◘ Gilead Sciences Inc.
◘ Cumberland Pharmaceuticals Inc

Note: Major Players are sorted in no particular order.

Market Detailed Segmentation:

By Drug Type:

Synthetic (sDMARD)
Conventional synthetic (csDMARDs)
Methotrexate
Sulfasalazine
Leflunomide
Hydroxychloroquine
Gold Salts
Targeted synthetic DMARDs (tsDMARDs)
Biological DMARDs (bDMARD)
Original DMARDs (boDMARDs)
Biosimilar DMARDs (bsDMARDs)
Primary
Secondary
Tertiary
Others

By Route of Administration :

Oral
Parenteral
Others
By Indication :

Rheumatoid Arthritis
Ankylosing Spondylitis
Psoriatic Arthritis
Systemic Lupus Erythematosus
Others

By Distribution Channel :

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

Buy This Premium Report and Get Upto 25 % OFF: https://www.coherentmarketinsights.com/insight/buy-now/5185

Furthermore, the years considered for the study are as follows:

Historical data - 2016-2021
The base year for estimation - is 2021
Estimated Year - 2023
Forecast period** - 2023 to 2030

This Disease Modifying Antirheumatic Drug Market Research/Analysis Report Contains Answers to your following Questions:

◈What are the current global trends in the Disease Modifying Antirheumatic Drug market, and will the market experience an increase or decrease in demand in the upcoming years?

◈ What is the expected demand for various product types within the Disease Modifying Antirheumatic Drug market, and what are the emerging Market applications and trends?

◈ What are the projections for the global Disease Modifying Antirheumatic Drug Market in terms of capacity, production, production value, cost, profit, market share, supply, consumption, import, and export?

◈ How will strategic developments shape the Market trajectory in the medium to long term?

◈ What factors contribute to the final price of Disease Modifying Antirheumatic Drug , and what are the raw materials used in its manufacturing?

◈ What is the market's growth potential, particularly with the increasing adoption of Disease Modifying Antirheumatic Drug in mining?

◈ What is the current and 2022 value of the global market, and who are the leading companies in this market?

◈ What recent Market trends can be leveraged to create additional revenue streams?

◈ What entry strategies, economic impact mitigation measures, and marketing channels should be considered for the Disease Modifying Antirheumatic Drug Market?

Summarized Extracts from TOC of Market Study

Chapter 1 Disease Modifying Antirheumatic Drug Introduction and Market Overview

1.1 Objectives of the Study

1.2 Overview of Disease Modifying Antirheumatic Drug

1.3 Scope of The Study

1.3.1 Key Market Segments

1.3.2 Players Covered

1.3.3 COVID-19's impact on the Disease Modifying Antirheumatic Drug industry

1.4 Methodology of The Study

1.5 Research Data Source

Chapter 2 Executive Summary

Chapter 3 Industry Chain Analysis

Chapter 4 Market, by Type

Chapter 5 Market, by Application

Chapter 6 Market Analysis by Regions

Chapter 7 North America Market Analysis by Countries

Chapter 8 Europe Disease Modifying Antirheumatic Drug Market Analysis by Countries

Chapter 9 Asia Pacific Disease Modifying Antirheumatic Drug Market Analysis by Countries

Chapter 10 Middle East and Africa Disease Modifying Antirheumatic Drug Market Analysis by Countries

Chapter 11 South America Disease Modifying Antirheumatic Drug Market Analysis by Countries

Chapter 12 Competitive Landscape

Chapter 13 Industry Outlook

Chapter 14 Market Forecast

Chapter 15 New Project Feasibility Analysis

Contact Us

Mr. Shah
Coherent Market Insights Pvt Ltd,
533 Airport Boulevard, Suite 400, Burlingame,
CA 94010, United States
Phone: US +12067016702 / UK +4402081334027
JAPAN:+81-50-5539-1737
INDIA:+91-848-285-0837
Email: sales@coherentmarketinsights.com

About Coherent Market Insights

Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.

This release was published on openPR.